BAM
BBIO icon

Bellevue Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Bellevue Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49
Closed -$3.75K – 385
2025
Q4 		$3.75K Buy
49
+11
+29% +$722 ﹤0.01% 371
2025
Q3 		$1.97K Buy
+38
New +$1.85K ﹤0.01% 436

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Asset Management's BBIO Position: Q1 2026 in Review

Bellevue Asset Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 49 shares — an estimated $3.75K sold.

Bellevue Asset Management first reported a position in BBIO in Q3 2025 and held it in 2 quarters. The position peaked at $3.75K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Bellevue Asset Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Bellevue Asset Management sold 49 BridgeBio Pharma shares in Q1 2026, an estimated $3.75K.
  • Bellevue Asset Management first reported a position in BridgeBio Pharma in Q3 2025 and held it in 2 quarters.
  • Bellevue Asset Management's BridgeBio Pharma position peaked at $3.75K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.